Component
Parkinson disease clinical progression
Parkinson disease clinical progression. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
The trial was stopped for futility; creatine did not improve the primary clinical progression comparison (P=0.45).
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/creatine-research/25668262.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f671e1277dae81047694ee994f7375030d1b744b83a5a7ffcf410b13b69cd419", "start_char": 0, "end_char": 2637, "text_sha256": "f671e1277dae81047694ee994f7375030d1b744b83a5a7ffcf410b13b69cd419"}
- experimental_model
- Multicenter double-blind randomized NET-PD LS-1 trial
- exposure
- Creatine monohydrate 10 g/day; median follow-up four years; planned five-year outcome
- limitations
- Stopped early for futility; distinguishes intended follow-up from actual median duration.
- nutrient_topic
- Creatine research collection; topical membership is not evidence of a direct dietary effect. · Creatine
- organism
- 1741 people with early treated Parkinson disease
- plain_language
- Long-term testing did not confirm the hoped-for clinical benefit for Parkinson disease.
- primary_references
- [creatine-p25668262] Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. (2015). https://pubmed.ncbi.nlm.nih.gov/25668262/ DOI: 10.1001/jama.2015.120
- tissue_or_cell_type
- Composite clinical progression
Creatine: synthesis, transport, phosphocreatine energetics and nutrient interactions (2026-09-17) · lines 1140–1151
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Multicenter double-blind randomized NET-PD LS-1 trial · source_derived_draft · unverified_draft
### creatine-parkinson-negative The trial was stopped for futility; creatine did not improve the primary clinical progression comparison (P=0.45). Condition category: normal nutrient_topic: Creatine research collection; topical membership is not evidence of a direct dietary effect. plain_language: Long-term testing did not confirm the hoped-for clinical benefit for Parkinson disease. organism: 1741 people with early treated Parkinson disease tissue_or_cell_type: Composite clinical progression experimental_model: Multicenter double-blind randomized NET-PD LS-1 trial limitations: Stopped early for futility; distinguishes intended follow-up from actual median duration. exposure: Creatine monohydrate 10 g/day; median follow-up four years; planned five-year outcome evidence_span: {"source_cache": "artifacts/creatine-research/25668262.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f671e1277dae81047694ee994f7375030d1b744b83a5a7ffcf410b13b69cd419", "start_char": 0, "end_char": 2637, "text_sha256": "f671e1277dae81047694ee994f7375030d1b744b83a5a7ffcf410b13b69cd419"} [creatine-p25668262] Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. (2015). https://pubmed.ncbi.nlm.nih.gov/25668262/ DOI: 10.1001/jama.2015.120
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.